A standalone business unit of Linuo Group, Shandong Keyuan Pharmaceutical Co., Ltd. (Keyuan Pharma) was founded in 2004. We are dedicated to the Research and Development, manufacturing and marketing of active pharmaceutical ingredients (APIs), intermediates and operating as a contract manufacturing organization (CMO).

Keyuan is a leading manufacturer of APIs in China, providing more than 20 high quality APIs manufactured at state-of-the-art production facilities, to nearly 200 customers in over 50 countries. Employing over 500 highly-trained professionals, Keyuan Pharma is wholly committed to environmental, health and safety (EHS) matters in all aspects of our business to ensure sustainable supplies.

Milestones

2023, Shandong Keyuan Pharmaceutical Co. LTD. Listing on Shenzhen Stock Exchange GEM

2022, Metformin Hydrochloride received CEP Certificate.

2021, Clemastine Fumarate obtained the CDE registration number

2020, Awarded the Shandong Provincial Technology Innovation Demonstration Enterprise by Shandong Provincial Department of Industry and Information Technology.

2019, Isosorbide Mononitrate, 70% diluted in lactose was certified by PMDA;

2017，Sets up a Metformin HCL auto manufacturing plant.

2016，Keyuan Pharma was successfully listed on NEEQ. Stock code: 836262.

2015，Passed the US FDA site inspection.

2014，lsosorbide Mononitrate successfully revised its CEP.

2014，Received Chinese new GMP certification.

2013，Gliclazide successfully revised its CEP.

2012，Certified by Japan's PMDA.

2009，lsosorbide mononitrate received CEP.

2009，14 APls and one FDF received Chinese GMP certification.

2007，Gliclazide received CEP.

2005，Four APls received Chinese GMP certification. Gliclazide was certified by KFDA.

2004，Keyuan Pharma incorporated as a company. Received 15 APls Chinese GMP certification.